Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Pembrolizumab (Keytruda®) on Biomarkers Related to Intratumoral Immunity, Proliferation and Apoptosis in Early Breast Cancer.

NCT03197389 is registered in ClinicalTrials.gov with Universitaire Ziekenhuizen KU Leuven as lead sponsor.

NCT NCT03197389
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03197389 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Pembrolizumab (Keytruda®) on Biomarkers Related to Intratumoral Immunity, Proliferation and Apoptosis in Early Breast Cancer.
Lead sponsor
Universitaire Ziekenhuizen KU Leuven
Phase
Phase 1
Overall status
Completed
Start date
January 18, 2018
Completion date
March 31, 2020
Enrollment
54 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, hormone receptor negative neoplasm, triple negative breast cancer